Company Overview
Snapshot
Founded in May 2022 by Nadav Grossinger, Elio Labs operates with 11–50 employees. The company has raised $21 million across two funding rounds from four investors.
Business overview
Elio Labs develops a technology platform that integrates advanced optical imaging with artificial intelligence to analyze biological samples. This solution provides high-resolution, real-time insights into cells and tissues, supporting applications in drug discovery, disease research, and experimental biology. The company's approach combines computational analysis with microscopy-based sensing to enhance the speed, accuracy, and scalability of biological data interpretation within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology.
Strategic signal
In July 2026, Elio Labs raised $21 million in a Series A funding round, signaling strong investor confidence in its AI-powered optical imaging platform. This capital infusion, led by Innovation Endeavors, validates the company's potential to significantly advance biological data interpretation for drug discovery and disease research, positioning Elio Labs for accelerated growth and product development in the health tech and life sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is Elio Labs' core technology?
- Elio Labs develops an AI-powered optical imaging platform that combines advanced optical imaging with artificial intelligence to analyze biological samples at high resolution and in real time.
- When was Elio Labs founded?
- Elio Labs was founded in May 2022.
- Who are the founders of Elio Labs?
- Nadav Grossinger is a co-founder and CEO of Elio Labs.
- What markets does Elio Labs serve?
- Elio Labs' technology supports applications in drug discovery, disease research, and experimental biology, primarily within the Health Tech & Life Sciences sector.